Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Joy Cuthberston, Steven Patterson, Finbarr O'Harte, Patrick Bell

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.
Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalMetabolism
Volume60
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint Dive into the research topics of 'Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus'. Together they form a unique fingerprint.

  • Cite this